Debt-to-equity of ARS Pharmaceuticals, Inc. from 30 Sep 2021 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
ARS Pharmaceuticals, Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2021 to 30 Sep 2025.
  • ARS Pharmaceuticals, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 65%, a 1828% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

ARS Pharmaceuticals, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 65% +62% +1828% 30 Sep 2025
Q2 2025 38% +35% +1313% 30 Jun 2025
Q1 2025 24% +21% +716% 31 Mar 2025
Q4 2024 14% +10% +290% 31 Dec 2024
Q3 2024 3% -1% -14% 30 Sep 2024
Q2 2024 3% -2% -40% 30 Jun 2024
Q1 2024 3% -6% -66% 31 Mar 2024
Q4 2023 3% -30% -90% 31 Dec 2023
Q3 2023 4% +38% 30 Sep 2023
Q2 2023 4% -28% -86% 30 Jun 2023
Q1 2023 9% -3% -29% 31 Mar 2023
Q4 2022 33% +27% +401% 31 Dec 2022
Q3 2022 -34% -40% -651% 30 Sep 2022
Q2 2022 33% 30 Jun 2022
Q1 2022 12% 31 Mar 2022
Q4 2021 7% 31 Dec 2021
Q3 2021 6% 30 Sep 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.